Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358709 | 1.00 | FOLH1 (0.54) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL29358689 | 1.00 | FOLH1 (0.54) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL1711313 | 1.00 | FOLH1 (0.54) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL1711315 | 1.00 | FOLH1 (0.54) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL29782763 | 0.97 | FOLH1 (0.51) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL29392005 | 0.95 | FOLH1 (0.47) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL16862514 | 0.94 | FOLH1 (0.49) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL16862515 | 0.94 | FOLH1 (0.49) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL30578949 | 0.93 | FOLH1 (0.48) | FOLH1CPB2SLC6A5GSRDPP4 | |
| SCHEMBL30093154 | 0.93 | FOLH1 (0.48) | FOLH1CPB2SLC6A5GSRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | IMMUNOGEN, INC. | 2025-01-09 | — | — | US | claimed |
| CN-113769108-B | Conjugates of cysteine engineered antibodies | 伊缪诺金公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4374850-A2 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | ImmunoGen, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117729942-A | Methods for increasing efficacy of ADAM 9-targeted immunoconjugates in the treatment of cancer | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117730098-A | Treatment of cancer in patients with soluble FR-alpha | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| WO-2022256507-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022192134-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | FOLH1 214/4885CPB2 2169/4885SLC6A5 1968/4885 |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | FOLH1 10/4885CPB2 129/4885SLC6A5 3167/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | FOLH1 214/4885CPB2 2169/4885SLC6A5 1968/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | FOLH1 3658/4885CPB2 3874/4885SLC6A5 1049/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | FOLH1 7/4885CPB2 2112/4885SLC6A5 3658/4885 |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | GABRA6, GABRA2, GABRA1 | FOLH1 3151/4885CPB2 1854/4885SLC6A5 1559/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | FOLH1 320/4885CPB2 1914/4885SLC6A5 483/4885 |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | FOLH1 1408/4885CPB2 2253/4885SLC6A5 4528/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | FOLH1 1408/4885CPB2 2253/4885SLC6A5 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.